John Domack News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Talk to their doctors. >> all right. dr. john, thanks very much. when we return, meta's new app threads draws millions, but will it landmark draws millions, but will it landmark zuckerberg in court? ♪ i have type 2 diabetes, ♪ ♪ but i manage it well. ♪ ♪ it's a a little pilill with a big storory to tell.l. ♪ ♪ i take e once-dailyly jardiaiance, ♪ ♪ at each d day's staaaaart.♪ ♪ a as time wenent on itit was easy y to seee ♪ ♪ i'm'm lowering g my a1c. ♪

I think it's helped me. >> reporter: his cognitive function has declined slightly, they say, but not by much. >> we get that it's not a cure. but there was nothing when we got our diagnosis, nothing. now there is something that we can do. >> reporter: it gives you hope? >> uh-huh, sure. >> yeah, unbelievably. i mean, we had none. >> reporter: since john is still in a trial, they're not paying for leqembi, but the list price is 26,500 a year. medicare plans to provide coverage as long as a doctor agrees to submit patient data. there are side effects. a greater risk of brain s swelling and brain...

>> reporter: they're traveling to london in august. >> alzheimer's threw us for a loop. this drug has thrown us a lifeline. >> reporter: kate snow, nbc news, new york. in the wake of last year's tripledemic, health officials are trying to prevent a repeat this fall. chief medical correspondent dr. john torres is here. john, last year we saw flu, rsv and covid all at the same time. >> lester, last winter we had the three virus, influenza, covid, rsv. they all ended up peaking at the same time. although these viruses don't typically occur all at once, this coming fall and winter might be a rep...

First-of-its-kind drug. it offers real hope for slowing progression of the disease. here is kate snow. >> reporter: it's the first time a drug meant to slow the progression of alzheimer's disease has ever been granted full regulatory approval. in a clinical trial involving about 1800 patients in the early stages of alzheimer's, the drug leqembi slowed cognitive decline by 27% over an 18-month period, compared to people who took a placebo. >> i really cannot overstate how important today is. this is really a game changer for our field. >> reporter: the drug targets a type of protein in the brai...